194 related articles for article (PubMed ID: 17397803)
1. FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70.
Wang Y; Wang SY; Zhang XH; Zhao M; Hou CM; Xu YJ; Du ZY; Yu XD
Biochem Biophys Res Commun; 2007 May; 356(4):998-1003. PubMed ID: 17397803
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of p210(bcr/abl) by curcumin involves disrupting molecular chaperone functions of Hsp90.
Wu LX; Xu JH; Huang XW; Zhang KZ; Wen CX; Chen YZ
Acta Pharmacol Sin; 2006 Jun; 27(6):694-9. PubMed ID: 16723087
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
Bali P; Pranpat M; Bradner J; Balasis M; Fiskus W; Guo F; Rocha K; Kumaraswamy S; Boyapalle S; Atadja P; Seto E; Bhalla K
J Biol Chem; 2005 Jul; 280(29):26729-34. PubMed ID: 15937340
[TBL] [Abstract][Full Text] [Related]
4. [The mechanism of apoptosis of chronic myeloid leukemia cells induced by the novel p210 bcr/abl inhibitor berbamine].
Sun JR; Zhang XH; He ZW; Gu Y; Yu YZ; Fang YM; Lü QH; Dong QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(32):2246-51. PubMed ID: 17064567
[TBL] [Abstract][Full Text] [Related]
5. Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors.
Lee SM; Bae JH; Kim MJ; Lee HS; Lee MK; Chung BS; Kim DW; Kang CD; Kim SH
J Pharmacol Exp Ther; 2007 Sep; 322(3):1084-92. PubMed ID: 17569822
[TBL] [Abstract][Full Text] [Related]
6. HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.
Rao R; Fiskus W; Yang Y; Lee P; Joshi R; Fernandez P; Mandawat A; Atadja P; Bradner JE; Bhalla K
Blood; 2008 Sep; 112(5):1886-93. PubMed ID: 18591380
[TBL] [Abstract][Full Text] [Related]
7. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor.
Kovacs JJ; Murphy PJ; Gaillard S; Zhao X; Wu JT; Nicchitta CV; Yoshida M; Toft DO; Pratt WB; Yao TP
Mol Cell; 2005 May; 18(5):601-7. PubMed ID: 15916966
[TBL] [Abstract][Full Text] [Related]
8. [Induction of molecular chaperones HSP70 and HSP90 in rat liver cytosol by a highly toxic coplanar PCB].
Fukuda A; Ishii Y; Tasaki K; Matsusue K; Ishida T; Oguri K
Fukuoka Igaku Zasshi; 1999 May; 90(5):259-71. PubMed ID: 10396883
[TBL] [Abstract][Full Text] [Related]
9. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.
Tabe Y; Jin L; Contractor R; Gold D; Ruvolo P; Radke S; Xu Y; Tsutusmi-Ishii Y; Miyake K; Miyake N; Kondo S; Ohsaka A; Nagaoka I; Andreeff M; Konopleva M
Cell Death Differ; 2007 Aug; 14(8):1443-56. PubMed ID: 17464329
[TBL] [Abstract][Full Text] [Related]
10. Additive viability-loss following hsp70/hsc70 double interference and Hsp90 inhibition in two breast cancer cell lines.
Håvik B; Bramham CR
Oncol Rep; 2007 Jun; 17(6):1501-10. PubMed ID: 17487411
[TBL] [Abstract][Full Text] [Related]
11. Substrate transfer from the chaperone Hsp70 to Hsp90.
Wegele H; Wandinger SK; Schmid AB; Reinstein J; Buchner J
J Mol Biol; 2006 Feb; 356(3):802-11. PubMed ID: 16403523
[TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
13. Evidence for chaperone heterocomplexes containing both Hsp90 and VCP.
Prince T; Shao J; Matts RL; Hartson SD
Biochem Biophys Res Commun; 2005 Jun; 331(4):1331-7. PubMed ID: 15883021
[TBL] [Abstract][Full Text] [Related]
14. The Hsp90 chaperone as a promising drug target.
Piper PW
Curr Opin Investig Drugs; 2001 Nov; 2(11):1606-10. PubMed ID: 11763165
[TBL] [Abstract][Full Text] [Related]
15. Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death.
Beck R; Verrax J; Gonze T; Zappone M; Pedrosa RC; Taper H; Feron O; Calderon PB
Biochem Pharmacol; 2009 Feb; 77(3):375-83. PubMed ID: 19014912
[TBL] [Abstract][Full Text] [Related]
16. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
[TBL] [Abstract][Full Text] [Related]
17. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.
Fiskus W; Ren Y; Mohapatra A; Bali P; Mandawat A; Rao R; Herger B; Yang Y; Atadja P; Wu J; Bhalla K
Clin Cancer Res; 2007 Aug; 13(16):4882-90. PubMed ID: 17699868
[TBL] [Abstract][Full Text] [Related]
18. The non-canonical Hop protein from Caenorhabditis elegans exerts essential functions and forms binary complexes with either Hsc70 or Hsp90.
Gaiser AM; Brandt F; Richter K
J Mol Biol; 2009 Aug; 391(3):621-34. PubMed ID: 19559711
[TBL] [Abstract][Full Text] [Related]
19. F1F0-ATP synthase functions as a co-chaperone of Hsp90-substrate protein complexes.
Papathanassiu AE; MacDonald NJ; Bencsura A; Vu HA
Biochem Biophys Res Commun; 2006 Jun; 345(1):419-29. PubMed ID: 16682002
[TBL] [Abstract][Full Text] [Related]
20. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases.
Furumai R; Matsuyama A; Kobashi N; Lee KH; Nishiyama M; Nakajima H; Tanaka A; Komatsu Y; Nishino N; Yoshida M; Horinouchi S
Cancer Res; 2002 Sep; 62(17):4916-21. PubMed ID: 12208741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
